A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke

Gil Benedek, Wenbin Zhu, Nicole Libal, Amanda Casper, Xiaolin Yu, Roberto Meza-Romero, Arthur Vandenbark, Nabil Alkayed, Halina Offner

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Chemoattraction of leukocytes into the brain after induction of middle cerebral artery occlusion (MCAO) increases the lesion size and worsens disease outcome. Our previous studies demonstrated that partial MHC class II constructs can reverse this process. However, the potential application of pMHC to human stroke is limited by the need to rapidly match recipient MHC class II with the β1 domain of the pMHC construct. We designed a novel recombinant protein comprised of the HLA-DRα1 domain linked to MOG-35-55 peptide but lacking the β1 domain found in pMHC and treated MCAO after 4 h reperfusion in humanized DR2 mice. Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of CD74 and other cell surface, cytokine and pathway markers. This study demonstrates that four daily treatments with DRα1-MOG-35-55 reduced infarct size by 40 % in the cortex, striatum and hemisphere, inhibited the migration of activated CD11b+CD45high cells from the periphery to the brain and reversed splenic atrophy. Furthermore, DRα1-MOG-35-55 bound to CD74 on monocytes and blocked both binding and downstream signaling of macrophage migration inhibition factor (MIF) that may play a key role in infarct development. The novel DRα1-MOG-35-55 construct is highly therapeutic in experimental stroke and could be given to all patients at least 4 h after stroke onset without the need for tissue typing due to universal expression of DRα1 in humans.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalMetabolic Brain Disease
Volume29
Issue number1
DOIs
StatePublished - 2014

Fingerprint

HLA-DR1 Antigen
Brain
Middle Cerebral Artery Infarction
Stroke
Macrophage Migration-Inhibitory Factors
Reperfusion
Recombinant Proteins
Histocompatibility Testing
Tissue
Cytokines
Peptides
Atrophy
Monocytes
Leukocytes
Therapeutics

Keywords

  • Immunotherapy
  • Inflammation
  • MHC class II invariant chain
  • Recombinant T-cell receptor Ligand
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Biochemistry
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke. / Benedek, Gil; Zhu, Wenbin; Libal, Nicole; Casper, Amanda; Yu, Xiaolin; Meza-Romero, Roberto; Vandenbark, Arthur; Alkayed, Nabil; Offner, Halina.

In: Metabolic Brain Disease, Vol. 29, No. 1, 2014, p. 37-45.

Research output: Contribution to journalArticle

Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R et al. A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke. Metabolic Brain Disease. 2014;29(1):37-45. https://doi.org/10.1007/s11011-013-9440-0
Benedek, Gil ; Zhu, Wenbin ; Libal, Nicole ; Casper, Amanda ; Yu, Xiaolin ; Meza-Romero, Roberto ; Vandenbark, Arthur ; Alkayed, Nabil ; Offner, Halina. / A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke. In: Metabolic Brain Disease. 2014 ; Vol. 29, No. 1. pp. 37-45.
@article{79c31e28ef684a0b8cf96763e8c60b6a,
title = "A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke",
abstract = "Chemoattraction of leukocytes into the brain after induction of middle cerebral artery occlusion (MCAO) increases the lesion size and worsens disease outcome. Our previous studies demonstrated that partial MHC class II constructs can reverse this process. However, the potential application of pMHC to human stroke is limited by the need to rapidly match recipient MHC class II with the β1 domain of the pMHC construct. We designed a novel recombinant protein comprised of the HLA-DRα1 domain linked to MOG-35-55 peptide but lacking the β1 domain found in pMHC and treated MCAO after 4 h reperfusion in humanized DR2 mice. Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of CD74 and other cell surface, cytokine and pathway markers. This study demonstrates that four daily treatments with DRα1-MOG-35-55 reduced infarct size by 40 {\%} in the cortex, striatum and hemisphere, inhibited the migration of activated CD11b+CD45high cells from the periphery to the brain and reversed splenic atrophy. Furthermore, DRα1-MOG-35-55 bound to CD74 on monocytes and blocked both binding and downstream signaling of macrophage migration inhibition factor (MIF) that may play a key role in infarct development. The novel DRα1-MOG-35-55 construct is highly therapeutic in experimental stroke and could be given to all patients at least 4 h after stroke onset without the need for tissue typing due to universal expression of DRα1 in humans.",
keywords = "Immunotherapy, Inflammation, MHC class II invariant chain, Recombinant T-cell receptor Ligand, Stroke",
author = "Gil Benedek and Wenbin Zhu and Nicole Libal and Amanda Casper and Xiaolin Yu and Roberto Meza-Romero and Arthur Vandenbark and Nabil Alkayed and Halina Offner",
year = "2014",
doi = "10.1007/s11011-013-9440-0",
language = "English (US)",
volume = "29",
pages = "37--45",
journal = "Metabolic Brain Disease",
issn = "0885-7490",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke

AU - Benedek, Gil

AU - Zhu, Wenbin

AU - Libal, Nicole

AU - Casper, Amanda

AU - Yu, Xiaolin

AU - Meza-Romero, Roberto

AU - Vandenbark, Arthur

AU - Alkayed, Nabil

AU - Offner, Halina

PY - 2014

Y1 - 2014

N2 - Chemoattraction of leukocytes into the brain after induction of middle cerebral artery occlusion (MCAO) increases the lesion size and worsens disease outcome. Our previous studies demonstrated that partial MHC class II constructs can reverse this process. However, the potential application of pMHC to human stroke is limited by the need to rapidly match recipient MHC class II with the β1 domain of the pMHC construct. We designed a novel recombinant protein comprised of the HLA-DRα1 domain linked to MOG-35-55 peptide but lacking the β1 domain found in pMHC and treated MCAO after 4 h reperfusion in humanized DR2 mice. Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of CD74 and other cell surface, cytokine and pathway markers. This study demonstrates that four daily treatments with DRα1-MOG-35-55 reduced infarct size by 40 % in the cortex, striatum and hemisphere, inhibited the migration of activated CD11b+CD45high cells from the periphery to the brain and reversed splenic atrophy. Furthermore, DRα1-MOG-35-55 bound to CD74 on monocytes and blocked both binding and downstream signaling of macrophage migration inhibition factor (MIF) that may play a key role in infarct development. The novel DRα1-MOG-35-55 construct is highly therapeutic in experimental stroke and could be given to all patients at least 4 h after stroke onset without the need for tissue typing due to universal expression of DRα1 in humans.

AB - Chemoattraction of leukocytes into the brain after induction of middle cerebral artery occlusion (MCAO) increases the lesion size and worsens disease outcome. Our previous studies demonstrated that partial MHC class II constructs can reverse this process. However, the potential application of pMHC to human stroke is limited by the need to rapidly match recipient MHC class II with the β1 domain of the pMHC construct. We designed a novel recombinant protein comprised of the HLA-DRα1 domain linked to MOG-35-55 peptide but lacking the β1 domain found in pMHC and treated MCAO after 4 h reperfusion in humanized DR2 mice. Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of CD74 and other cell surface, cytokine and pathway markers. This study demonstrates that four daily treatments with DRα1-MOG-35-55 reduced infarct size by 40 % in the cortex, striatum and hemisphere, inhibited the migration of activated CD11b+CD45high cells from the periphery to the brain and reversed splenic atrophy. Furthermore, DRα1-MOG-35-55 bound to CD74 on monocytes and blocked both binding and downstream signaling of macrophage migration inhibition factor (MIF) that may play a key role in infarct development. The novel DRα1-MOG-35-55 construct is highly therapeutic in experimental stroke and could be given to all patients at least 4 h after stroke onset without the need for tissue typing due to universal expression of DRα1 in humans.

KW - Immunotherapy

KW - Inflammation

KW - MHC class II invariant chain

KW - Recombinant T-cell receptor Ligand

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84895866825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895866825&partnerID=8YFLogxK

U2 - 10.1007/s11011-013-9440-0

DO - 10.1007/s11011-013-9440-0

M3 - Article

C2 - 24122483

AN - SCOPUS:84895866825

VL - 29

SP - 37

EP - 45

JO - Metabolic Brain Disease

JF - Metabolic Brain Disease

SN - 0885-7490

IS - 1

ER -